1699.8000 33.40 (2.00%)
NSE May 29, 2025 15:31 PM
Volume: 2.4M
 

Change is hard, and some Indian pharma companies are embracing it better than others
By Tejas MD

 

For Indian pharma companies, pandemic treatments became a significant moneymaker in FY22. Post-Covid, drug markers are shifting their attention back to their core product portfolio. 

This comes at a time when the US formulation business, which used to be a significant revenue contributor for Indian pharma, is facing intense competition in the generics space. Drug makers that quickly adapt …

Premium This is a premium article. Click here to read.

Sun Pharmaceutical I.. has an average target of 2039.89 from 9 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended